Connect with us

FDA to Hold Public Hearing on Cannabis in the U.S.

Published

on

[dropcap class=”kp-dropcap”]O[/dropcap]n May 31, the Food and Drug Administration (FDA) will hold a public meeting to discuss scientific data about cannabis and cannabis-derived products, including highly anticipated discussion on cannabidiol (CBD).

Held between the hours of 8am and 6pm eastern daylight time (or 5am-3pm pacific), the FDA’s meeting at the organization’s campus in Maryland will seek to “obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds.” Those who will be present at the meeting have prepared oral presentations and comments on the subject. However comments submitted digitally or in written form will be accepted until July 2.

The gathering is being called to as “Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments,” and for many, is a long overdue plan to talk about cannabis in the future of the country. It’s an exciting time to see the FDA working with the right people to bring cannabis into the next decade. According to the FDA’s summary, it is because of public interest that this hearing will finally occur. “Given the substantial interest in this topic and Congressional interest in fostering the development of appropriate hemp products under the 2018 Farm Bill, while also preserving FDA’s ability to protect the public health, FDA is holding a public hearing,” the FDA wrote. “The goal of the hearing is to obtain additional scientific data and other information related to cannabis and cannabis-derived compounds, both from botanical and synthetic sources, to inform our regulatory oversight of these products. FDA does not intend for this hearing to produce any decisions or new positions on specific regulatory questions, but this hearing is expected to be an important step in our continued evaluation of cannabis and cannabis-derived compounds in FDA-regulated products.”

For those who cannot attend the hearing in person due to limited space, there will be a live stream of the hearing if you follow the instructions here.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *